Table 2

Outcomes and adverse events

N=19
Suspected infarct localisation, no./total no. (%)
 Anterior wall infarction9/19 (47%)
 Posterior wall infarction10/19 (53%)
Pre-PCI TIMI grade flow*, no./total no. (%)
 013/19 (68%)
 13/19 (16%)
 20
 33/19 (16%)
Culprit lesion, no./total no. (%)
 No significant coronary stenosis3/19 (16%)
 Left main artery1/19 (5%)
 Left anterior descending artery9/19 (47%)
 Circumflex artery2/19 (11%)
 Right coronary artery4/19 (21%)
Post-PCI TIMI grade flow*, no./total no. (%)
 01/19 (5%)
 10
 21/19 (5%)
 317/19 (90%)
Peak level of creatine kinase, units/L (IQR)†3807 (1429–5585)
Peak level of troponin T, ng/mL (IQR)†4.56 (2.50–10.00)
Killip classification, no./total no. (%)
 I13/19 (68%)
 II3/19 (16%)
 III2/19 (11%)
 IV1/19 (5%)
Recurrent ischaemia, no./total no. (%)0
Major cardiac arrhythmias, no./total no. (%)
 Ventricular tachycardia2/19 (11%)
 Ventricular fibrillation0
 Asystole0
 AV-Block ≥2°0
Stroke0
Major/minor bleeding§0
Cardiac arrest1/19 (5%)
Death1/19 (5%)
NYHA class at day 30§
 I10/18 (56%)
 II6/18 (33%)
 III2/18 (11%)
 IV0
Infection within 30 days, no./total no. (%)3/19 (16%)

  • *TIMI grade flow prior/after percutaneous coronary intervention.

  • †of 15 patients with percutaneous coronary intervention.

  • ‡according to thrombolysis in myocardial infarction bleeding score.

  • §NYHA category of 18 patients survived to follow-up.

  • NYHA, New York Heat Association; PCI, percutaneous coronary intervention; TIMI, thrombolysis in myocardial infarction.